Welcome to the Investor Relations pages for Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.
The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:
By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.
Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain.
Midatech’s ordinary shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (CUSIP number GB00BKT14T00). Midatech’s American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol MTP (CUSIP No. 59564R302).
The information disclosed in these pages is in accordance with Rule 26 of the Aim Rules. The investor site was most recently updated on 4 March 2020.